Vanda (VNDA) Q1 2026 Earnings Call Transcript

Vanda Pharmaceuticals reported Q1 2026 net product sales of $51.7 million, up 3% year over year, led by Fanapt sales growth of 26% to $29.6 million and supported by the U.S. launch of Nirius and FDA approval of Dysanti. Management raised full-year 2026 revenue guidance to $240 million-$290 million from $230 million-$260 million, including $10 million-$30 million from Nirius, while warning that cash burn will likely exceed 2025 levels. Offsetting the positives, Hetlioz sales fell 24% to $15.9 million on generic competition and the company posted a wider net loss of $48.6 million.

Analysis

VNDA is transitioning from a single-product decline story to a two-step monetization curve: near-term Fanapt acceleration plus a longer-dated portfolio optionality stack. The market is likely underestimating how much of the current re-rate hinges on sales-force productivity rather than pure demand creation; the step-up in reps and call volume can keep Fanapt compounding for several quarters even if underlying class growth is only average. The key second-order effect is that higher Fanapt share gains now may be partially self-financing if management can use the franchise to subsidize Dysanti launch economics before generic pressure fully bites.

The biggest imbalance is between headline launch enthusiasm and actual cash conversion. Nirius is being modeled off TAM, not observed demand, which makes this more of a sentiment catalyst than a forecastable earnings driver for the next two quarters; that creates upside optionality but also a high probability of revenue disappointment if early access friction is higher than expected. Meanwhile, the direct-to-consumer channel is strategically interesting because it may bypass traditional reimbursement drag, but it also concentrates execution risk in paid acquisition efficiency and repeat-order behavior, which the Street is not yet pricing with much discipline.

The more important hidden risk is that VNDA is using growth launches to mask a deteriorating core cash profile. With cash burn set to rise and Hetlioz structurally fading, the equity story becomes increasingly dependent on Fanapt sustaining growth and one or more pipeline assets converting within 12-18 months. If Dysanti or imsidolimab slips, the stock can quickly shift from ‘multi-asset growth’ to ‘serial dilution risk,’ especially once investors stop giving credit for pre-launch revenue ramps.

Consensus appears too complacent on the launch-to-revenue lag and too optimistic on the durability of the existing commercial base. The market may also be underpricing the fact that the best near-term hedge for VNDA is not long-only exposure, but owning upside to Fanapt while fading the valuation on unproven launches. In other words, the stock can work if execution stays perfect; the asymmetry improves if you separate the known commercial asset from the uncertain launch basket.

Key Decisions for Investors

• Long VNDA common into the next 1-2 quarters only if using a tight risk box around Fanapt prescription momentum; target a 15-25% upside move if April trends persist, but cut if weekly TRx rolls over for two consecutive monthly checks.
• Sell downside via VNDA put spreads 3-6 months out to express the view that the stock is supported by Fanapt growth and near-term launch optimism, while capping risk if Nirius uptake disappoints.
• Pair trade: long VNDA / short a basket of late-stage biotech names with no commercial base for 6-12 months; the relative winner should be the company with actual revenue and a visible sales-force lever, not just pipeline optionality.
• If seeking a lower-risk expression, wait for any post-earnings pullback and buy VNDA only after confirmation that Nirius access metrics and Dysanti launch timing are not slipping; otherwise the risk/reward favors patience over chasing the headline guidance raise.
• Monitor for any signs of Fanapt inventory normalization or sequential TRx flattening; if that happens, fade VNDA aggressively because the stock’s current thesis is disproportionately dependent on one product carrying the valuation.